Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults by A. P. Yu et al.
Yu et al. Diabetol Metab Syndr  (2015) 7:111 
DOI 10.1186/s13098-015-0108-2
RESEARCH
Association of endothelin-1 and matrix 
metallopeptidase-9 with metabolic syndrome 
in middle-aged and older adults
A. P. Yu, B. T. Tam, W. Y. Yau, K. S. Chan, S. S. Yu, T. L. Chung and P. M. Siu*
Abstract 
Background: Metabolic syndrome (MetS) contains a cluster of cardiovascular risk factors. People with MetS are more 
susceptible to cardiovascular disease, diabetes mellitus, and cancer. Endothelin-1 (ET-1) and matrix metallopepti-
dase-9 (MMP-9) have been implicated in the development of cardiovascular diseases, diabetes mellitus and cancers. 
This cross-sectional study aimed to examine the association of ET-1 and MMP-9 with MetS in middle-aged and older 
Hong Kong Chinese adults.
Methods: 149 adults aged 50 to 92 (n = 75 for non-MetS group and n = 74 for MetS group) were examined. All 
subjects were screened for MetS according to the diagnostic guideline of the United States National Cholesterol 
Education Program (NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria. Serum levels of ET-1 and MMP-9 were 
measured. Independent t test was used to detect differences between non-MetS and MetS groups and between sub-
jects with or without certain metabolic abnormality. The association of the serum concentration of MMP-9 and ET-1 
with MetS parameters were examined by Pearson’s correlation analysis.
Results: Serum level of ET-1 is higher in MetS-positive subjects and in subjects with high blood pressure, elevated 
fasting blood glucose, and central obesity. The serum concentration of MMP-9 is higher in subjects positively diag-
nosed with MetS and subjects with high blood pressure, elevated fasting blood glucose, low blood high-density 
lipoprotein-cholesterol (HDL-C), high blood triglycerides, and central obesity. Correlation analyses revealed that serum 
concentration of ET-1 is positively correlated to systolic blood pressure, waist circumference, fasting blood glucose, 
and age whereas it is negatively correlated to HDL-C. MMP-9 is positively correlated to systolic blood pressure, waist 
circumference, fasting blood glucose, and age whereas it is negatively correlated to HDL-C.
Conclusion: Serum ET-1 is higher in subjects with hypertension, hyperglycemia, central obesity or MetS. Serum 
MMP-9 is higher in subjects diagnosed with MetS or having either one of the MetS parameters. Both circulating levels 
of ET-1 and MMP-9 are correlated to systolic blood pressure, waist circumference, fasting blood glucose, HDL-C, and 
age. Further research is needed to fully dissect the role of ET-1 and MMP-9 in the development of cancers, diabetes 
and cardiovascular disease in relation to MetS.
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Background
Metabolic syndrome (MetS) is regarded as a sub-health 
status that contains a clustering of cardiovascular risk 
factors, including high blood pressure, central obesity, 
insulin resistance, hypertriglyceridemia and dyslipidemia 
[1–4]. People diagnosed with MetS are known to be more 
susceptible to develop diabetes mellitus [5], cardiac vas-
cular diseases [6], and cancers [7, 8]. It has been demon-
strated that the circulating levels of ET-1 and MMP-9 are 
higher in patients with diabetes mellitus [9, 10], cardio-
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ET-1 is a 21 amino acids-long vasoconstrictor, mito-
gen and pro-inflammatory peptide which is mainly pro-
duced in endothelial cells in small amount under normal 
physiological condition [15, 16]. However, its abundance 
is highly increased during pathological conditions due 
to the stimulated production in different types of cell 
including endothelial cells, cardiac myocytes, smooth 
muscle cells and inflammatory cells [11, 17, 18]. Studies 
have revealed that ET-1 also contributes to several patho-
logical events including inflammation [19–22], fibrosis 
[23], cardiac and vascular hypertrophy [24] and prolif-
eration of vascular smooth muscle cells and fibroblasts 
[24]. The upregulation of ET-1 is regarded as an impor-
tant pathogenic factor of the development of cardiovas-
cular diseases [11]. Removal of ET-1 in cardiomyocytes 
has been demonstrated to ameliorate the cardiac remod-
eling caused by Trypanosoma cruzi-induced heart dis-
ease [25]. Elevated plasma ET-1 level is also observed in 
patients of diabetes mellitus [9] and cardiovascular dis-
eases [11] while ET-1 has been suggested to be related 
to the promotion of cancer development by modulating 
mitosis, angiogenesis and apoptosis [13].
Matrix metalloproteinases (MMP) is a protein fam-
ily of zine-dependent endopeptidases that regulate tis-
sue remodeling under both normal physiological and 
pathological conditions [12]. Among them, MMP-9, also 
known as gelatinase B or 92-kDa type IV collagenase, is 
responsible for the degradation of extracellular matrix 
[12]. Abundance of MMP-9 is increased in several car-
diovascular diseases including hypertension [26], athero-
sclerosis [27] and myocardial infarction [28]. Elevation of 
MMP-9 abundance may initiate or exacerbate the patho-
genesis due to immune response stimulated by its proteo-
lytic property [12, 28]. It has been demonstrated that the 
circulating level of MMP-9 is increased under hypergly-
cemia condition [29]. General deletion or target deletion 
of MMP-9 has been shown to alleviate the pathological 
conditions caused by downregulation of ET-1, hence pre-
vented enlargement of left ventricle under myocardial 
infarction by reducing the inflammatory response and 
improving left ventricle remodeling in the permanent 
occlusion model of myocardial infarction [30]. These 
results support the genetic studies showing that MMP-9 
plays an important role in cardiovascular diseases [12, 
30]. MMP-9 has also been shown to be involved in angio-
genesis [31] and metastasis of certain cancers [32].
ET-1 and MMP-9 are both endothelial biomarkers that 
may contribute to the development of endothelial dys-
function and are involved in cardiac remodeling and the 
development of cardiovascular diseases [33]. Notably, 
one of the underlying causes of diabetic angiopathy, car-
diovascular diseases, diabetes mellitus and its complica-
tions was thought to be related to endothelial dysfunction 
[34]. It has been previously demonstrated by a popula-
tion-based study that the increase in circulating endothe-
lial biomarkers, such as ET-1 and MMP-9, can be used to 
evaluate the endothelial function and predict the risk of 
diabetes [35]. The change in these endothelial biomark-
ers may provide clues to evaluate the high susceptibility 
to cardiovascular diseases, diabetes mellitus and cancers 
for people with MetS. This cross-sectional study aimed to 
examine the association of ET-1 and MMP-9 with MetS 
in middle-aged and older Hong Kong Chinese adults.
Methods
Middle-aged and older Hong Kong Chinese adults with 
age ranged from 50 to 92 including 75 MetS negative 
and 74 MetS positive subjects were voluntarily recruited. 
Participants with dementia or mental disorders, severe 
or acute cardiovascular diseases, post-stroke, neuro-
musculoskeletal illness, acute medical illness, sympto-
matic heart or lung diseases, severe rheumatoid arthritis, 
osteoarthritis or pulmonary illness and participants who 
were immobile, smoker or under treatment for metabolic 
abnormalities were excluded in this study. Subjects were 
informed about the potential risks and benefits of their 
participation, and written informed consent was obtained 
on a voluntary basis before the study began. All the 
experimental procedures received human research eth-
ics approval from The Hong Kong Polytechnic University 
(HSEARS20150116001 and HSEARS20150116002). All 
subjects were screened for MetS according to the diag-
nostic guideline of the United States National Cholesterol 
Education Program (NCEP) Expert Panel Adult Treat-
ment Panel (ATP) III criteria. Individuals diagnosed with 
MetS have more than two of following characteristics: (1) 
central obesity (waist circumference exceeds 90 or 80 cm 
for Asian male and female, respectively), (2) hypertension 
(systolic pressure equals or exceed 130  mmHg or dias-
tolic pressure equals or exceeds 85 mmHg), (3) elevated 
blood glucose (fasting glucose level equals or exceeds 
5.5 mmol/L [100 mg/dL]), (4) elevated plasma triglycer-
ides (level equals or exceeds 1.70 mmol/L [150 mg/dL]), 
and (5) low level of high-density lipoprotein-cholesterol 
(HDL-C; level equals or is less than 40  mg/dL for male 
and 50 mg/dL for female) are regarded as MetS positive.
Measurement of MetS diagnostic parameters and the 
circulating endothelial biomarkers
MetS diagnostic parameters including blood pressure, 
waist circumference, fasting blood glucose, blood tri-
glycerides and blood HDL-C were measured. Systolic 
blood pressure, diastolic blood pressure and waist cir-
cumference were measured by trained research person-
nel. Blood pressure measurement was determined on 
the right arm after 5-min seated rest using an electronic 
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blood pressure monitor (Accutorr Plus, Datascope). 
Systolic and diastolic blood pressure was obtained over 
the brachial artery region with the arm supported at 
heart level using appropriate sized cuff. The average of 
two measurements taken with a 1-min interval between 
them was recorded for analysis. Waist circumference was 
measured midway between the lowest rib and the supe-
rior border of the iliac crest using an inelastic measuring 
tape on the bare skin and recorded to the nearest 0.1 cm. 
The tape was snugged horizontally around the abdomen 
passing across the navel without causing compression 
on the skin. Measurement was performed at the end of 
normal expiration. Fasting venous blood samples were 
collected after a minimum 10  h fast by certified phle-
botomists for biochemical measurements. Fasting blood 
glucose, blood triglycerides, and blood HDL-cholesterol 
concentrations were measured by an accredited medi-
cal laboratory by commercial test kit methods using an 
automatic clinical chemistry analyser (Architect CI8200, 
Abbott Diagnostics). The serum ET-1 level was assayed 
by a commercially available chemiluminescent enzyme-
linked immunoassay kit (QuantiGlo® Human Endothe-
lin-1 Chemiluminescent Immunoassay, R&D Systems, 
USA) and the serum MMP-9 level was detected by 
Biotrak™ MMP-9 activity assay (GE Healthcare) accord-
ing to the protocols provided by manufacturers.
Statistical analysis
Subjects were grouped according to different criteria 
including their MetS status and the presence of each 
cardio-metabolic abnormality. Data are expressed as 
mean ± standard deviation. Normalities of the data were 
examined. The statistical differences of subjects’ gender 
ratios with certain cardio-metabolic abnormality were 
assessed by Chi square test. The differences between two 
groups were detected by independent t test. Pearson’s 
correlation analysis was performed to examine the cor-
relation between the serum concentration of MMP-9 and 
ET-1 to the MetS parameters. All statistical analyses were 
performed using the Statistical Package for the Social 
Sciences (SPSS) version 21 for Windows. Statistical sig-
nificance was accepted at p < 0.05.
Results
One hundred and forty-nine adults (n = 75 for MetS neg-
ative subjects and n = 74 for MetS positive subjects) were 
included in this cross-sectional study. The gender ratio 
of female-to-male was 83-to-66. The number of subjects, 
gender ratio and age of subjects with certain cardio-
metabolic abnormality are summarized in Table  1. It is 
observed that the age of the subjects with central obesity 
(P  =  0.038) and with dyslipidemia (P  =  0.001) are sig-
nificantly higher than those without in the present study. 
The gender ratios of subjects with certain cardio-meta-
bolic abnormality are not significantly different (Table 1).
The systolic blood pressure (Fig. 1a), diastolic pressure 
(Fig.  1b), waist circumference (Fig.  1c), blood triglyc-
erides (Fig.  1d) and fasting blood glucose (Fig.  1f ) are 
all significantly higher in subjects with MetS compared 
to MetS-negative subjects. The blood HDL-C in MetS 
positive subjects is significantly lower when compared to 
those without MetS (Fig. 1e).
The serum ET-1 concentration is significantly higher 
in the MetS-positive subjects when compared to the 
MetS-negative subjects (P = 0.006) (Fig. 2a). The serum 
concentration of ET-1 in subjects with hypertension 
(P = 0.001) (Fig. 2b), central obesity (P = 0.006) (Fig. 2c), 
and high fasting blood glucose (P  =  0.03) (Fig.  2f ) are 
significantly higher than those without. The serum con-
centration of MMP-9 in subjects diagnosed with MetS 
(P = 0.001) (Fig. 3a), hypertension (P = 0.001) (Fig. 3b), 
central obesity (P =  0.001) (Fig.  3c), high blood triglyc-
erides (P = 0.018) (Fig. 3d), dyslipidemia or low HDL-C 
(P  =  0.001) (Fig.  3e), and high fasting blood glucose 
(P = 0.012) (Fig. 3f ) are significantly higher than subjects 
negatively diagnosed with those parameters. Neither the 
circulating level of ET-1 nor MMP-9 has shown a sig-
nificant difference between male and female (data not 
shown).
The correlation analyses revealed that the concentra-
tion of ET-1 was positively correlated to systolic blood 
pressure (P = 0.001, R = 0.423) (Fig. 4a), waist circumfer-
ence (P = 0.001, R = 0.274) (Fig. 4c), fasting blood glu-
cose (P = 0.002, R = 0.253) (Fig. 4f ) and age (P = 0.001, 
R  =  0.276) (Fig.  4g) whereas negatively correlated to 
HDL-C (P = 0.001, R = 0.394) (Fig. 4e). Similar pattern 
was observed in the correlation analyses of the serum 
concentration of MMP-9. The level of MMP-9 was posi-
tively correlated to systolic blood pressure (P  =  0.001, 
R  =  0.387) (Fig.  5a), waist circumference (P  =  0.001, 
R  =  0.305) (Fig.  5c), fasting blood glucose (P  =  0.001, 
R = 0.321) (Fig. 5f ), age (P = 0.001, R = 0.304) (Fig. 5g) 
and negatively correlated to HDL-C (P  =  0.001, 
R = 0.390) (Fig. 5e).
Discussion
MetS is a cluster of cardiovascular risk factors and people 
with MetS are known to be more susceptible to develop 
cardiovascular diseases, diabetes mellitus and common 
cancers [1–4]. A meta-analysis has revealed that the inci-
dent rate of people with metabolic syndrome of having 
cardiovascular disease, coronary heart disease and stroke 
is 50 % higher than healthy control [6]. Elevation of cir-
culating levels of both ET-1 and MMP-9 are observed 
in patients with cardiovascular diseases, diabetes melli-
tus and cancers. Endothelium has been indicated as the 
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primary site of dysfunction in cardiovascular disease 
while endothelial dysfunction has been hypothesized as 
one of the underlying causes for diabetes mellitus and its 
complications [34, 36]. Elevations of ET-1 and MMP-9 in 
the circulating system have been suggested to be associ-
ated with the development of endothelial dysfunction 
[33, 37]. The changes in circulating levels of ET-1 and 
MMP-9 might be associated with the possible mecha-
nisms such as endothelial dysfunction that might help to 
explain why people with MetS have a higher chance of 
developing cardiovascular diseases, diabetes mellitus and 
cancers.
Elevated circulating levels of ET‑1 and MMP‑9 in people 
with MetS might be associated with the increased risk 
of developing cardiovascular diseases and diabetes 
mellitus
ET-1 is a vasoconstrictor responsible for reducing heart 
rate, cardiac output and increasing mean arterial blood 
pressure via ET receptor [11]. Contribution of the ele-
vation of plasma ET-1 to the development of clinical 
hypertension, vascular dysfunction and cardiac vascular 
diseases have been well recognized [11]. Yang and col-
leagues have generated a line of conditional overexpress-
ing transgenic mice by inserting a human ET-1 cDNA to 
the downstream of alpha-MHC promoter to investigate 
the consequence of ET-1 overexpression in heart [21]. 
They observed increase in left ventricular endocardial 
circumference together with macrophages and T-cells 
infiltration, suggesting that upregulation of ET-1 may 
cause inflammation and dilated cardiomyopathy [21]. The 
normal range of the circulating ET-1 is 1.41 ± 0.50 pg/ml 
[38], which is consistent with the results reported in the 
present study. Subjects with MetS are demonstrated to 
have a higher circulating level of ET-1 when compared to 
healthy control, which might contribute to the higher risk 
of cardiovascular diseases in people with MetS. Our data 
also show that subjects with either elevated fasting blood 
glucose, central obesity or hypertension have higher 
serum level of ET-1. The serum concentration of ET-1 
is found to be significantly correlated to systolic blood 
pressure, waist circumference, blood HDL-C and fasting 
blood glucose. The plasma ET-1 level has been reported 
to be elevated in patients with diabetes mellitus [9]. It has 
been demonstrated that hyperglycemia upregulates ET-1 
in endothelial cells by mediating through AMPK-C/EBP 
signaling pathway [39]. Parrinello and colleagues com-
pared the plasma concentrations of ET-1 in people with 
central obese normotensive and central obese hyper-
tensive to lean normotensive people [40]. They have 
observed that both subjects with central obese normo-
tensive and central obese hypertensive have significantly 
higher plasma concentration of ET-1 when compared to 
lean normotensive subjects [40]. Our results are in line 
with these findings that significantly higher abundance 
of ET-1 is found in subjects with central obesity. Leung 
and colleagues have demonstrated that chronic overex-
pression of ET-1 in endothelial cells results in elevation of 
blood pressure in a transgenic mice model [41]. In addi-
tion, a human study observed that both hypertensive and 
non-hypertensive subjects with phaeochromocytoma 
have a significantly higher level of ET-1 when compared 
to those with essential hypertension and healthy con-
trol [42]. Notably, association between the highest ET-1 
Table 1 Background information of subjects
P = 0.001
General information of recruited subjects
Age 64.6 ± 9.6 years (Range: 50–92)
Gender ratio (F:M) 83:66
Information of subjects positively  
diagnosed with

















75 62.29 ± 7.17 41:34 74 67.03 ± 11.09 42:32 0.002 0.797
Hypertension 61 63.03 ± 7.45 37:24 88 65.76 ± 10.73 46:42 0.069 0.331
Central Obesity 69 62.94 ± 7.02 36:33 80 66.11 ± 11.19 47:33 0.038 0.420
Hypertriglyceri-
demia
101 64.18 ± 7.80 54:47 48 65.63 ± 11.12 29:19 0.431 0.425
Dyslipidemia 
(low HDL-C)
94 61.34 ± 7.08 50:44 55 70.29 ± 10.70 33:22 0.001 0.419
Hyperglycemia 103 64.29 ± 8.91 60:43 46 65.43 ± 11.03 23:23 0.538 0.349
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level and the presence of hypertension has been shown 
in those subjects with phaeochromocytoma, suggesting 
that ET-1 might play a role in the development of clinical 
hypertension [42]. In the present study, it is observed 
that subjects with hypertension have a higher serum level 
of ET-1 when compared to non-hypertensive subjects. 
Fig. 1 MetS parameters in subjects with or without MetS and metabolic abnormalities. a Systolic pressure in subjects with or without MetS. 
b Diastolic pressure in subjects with or without MetS. c Waist circumference in subjects with or without MetS. d Blood triglycerides in subjects 
with or without MetS. e HDL-C in subjects with or without MetS. f Fasting blood glucose in subjects with or without MetS. Data are expressed as 
mean ± standard deviation. The differences between two groups were detected by independent t-test. Statistical significance was accepted at 
p < 0.05
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Fig. 2 Serum level of ET-1 in subjects with or without MetS and metabolic abnormalities. a Serum level of ET-1 in subjects with or without MetS. b 
Serum level of ET-1 in subjects with or without hypertension. c Serum level of ET-1 in subjects with or without central obesity. d Serum level of ET-1 
in subjects with or without hypertriglyceridemia. e Serum level of ET-1 in subjects with or without dyslipidemia (low HDL-C). f Serum level of ET-1 in 
subjects with or without hyperglycemia. Data are expressed as mean ± standard deviation. The differences between two groups were detected by 
independent t-test. Statistical significance was accepted at p < 0.05
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Fig. 3 Serum level of MMP-9 in subjects with or without MetS and metabolic abnormalities. a Serum level of MMP-9 in subjects with or without 
MetS. b Serum level of MMP-9 in subjects with or without hypertension. c Serum level of MMP-9 in subjects with or without central obesity. d 
Serum level of MMP-9 in subjects with or without hypertriglyceridemia. e Serum level of MMP-9 in subjects with or without dyslipidemia (low HDL-
C). f Serum level of MMP-9 in subjects with or without hyperglycemia. Data are expressed as mean ± standard deviation. The differences between 
two groups were detected by independent t-test. Statistical significance was accepted at p < 0.05
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Fig. 4 Correlation analysis of serum level of ET-1 to parameters of metabolic syndrome. a Correlation between serum level of ET-1 and systolic blood pres-
sure. b Correlation between serum level of ET-1 and diastolic blood pressure. c Correlation between serum level of ET-1 and waist circumference. d Correla-
tion between serum level of ET-1 and blood triglycerides. e Correlation between serum level of ET-1 and blood HDL-C. f Correlation between serum level of 
ET-1 and fasting blood glucose. g Correlation between serum level of ET-1 and age. Pearson’s correlation analysis was performed. Statistical significance was 
accepted at p < 0.05. Black diamond refers to the data of MetS-positive subjects. Open triangle refers to the data of MetS-negative subjects
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Fig. 5 Correlation analysis of serum level of MMP-9 to parameters of metabolic syndrome. a Correlation between serum level of MMP-9 and 
systolic blood pressure. b Correlation between serum level of MMP-9 and diastolic blood pressure. c Correlation between serum level of MMP-9 and 
waist circumference. d Correlation between serum level of MMP-9 and blood triglycerides. e Correlation between serum level of MMP-9 and blood 
HDL-C. f Correlation between serum level of MMP-9 and fasting blood glucose. g Correlation between serum level of MMP-9 and age. Pearson’s cor-
relation analysis was performed. Statistical significance was accepted at p < 0.05. Black diamond refers to the data of MetS-positive subjects. Open 
triangle refers to the data of MetS-negative subjects
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Hypertension has been shown to be highly associated 
with obesity [43, 44]. It is speculated that the obesity-
associated increase in ET-1 might, at least partly, con-
tribute to the development of hypertension and results 
in a high association between obesity and hyperten-
sion. Similarly, hyperglycemia-induced elevation of ET-1 
might lead to changes in vascular structure and vascular 
function hence results in hypertension. The obesity-asso-
ciated increase in ET-1 and hyperglycemia-induced ele-
vation of ET-1 might partly explain the high association 
between hypertension and obesity as well as between 
hypertension and hyperglycemia.
Matrix metalloproteinases are the family of proteins 
responsible for cleaving the structural elements of the 
extracellular matrix (ECM) during physiological and 
pathological ECM remodeling. MMP-9, also known as 
gelatinase B or 92-kDa type IV collagenase belongs to 
the gelatinase subgroup of the matrix metalloproteinases 
family [12]. The circulating MMP-9 in healthy people 
normally ranges from 30 ng/ml to 537 ng/ml [45]. In the 
present study, serum levels of MMP-9 in subjects with 
or without MetS are fallen in the normal range. How-
ever, the serum level of MMP-9 is significantly elevated 
in subjects with MetS and subjects with either one of the 
cardio-metabolic abnormalities (i.e., central obesity, low 
HDL-C, hypertension, elevated fasting blood glucose and 
high blood triglycerides), suggesting that any one of the 
cardio-metabolic abnormalities might be associated with 
the elevation of circulating MMP-9. This perspective is 
also partly supported by our correlation analyses, which 
demonstrate the positive correlation between serum 
MMP-9 and systolic pressure, waist circumference and 
fasting blood glucose, as well as a negative correlation 
between serum MMP-9 and HDL-C. Of note, our results 
are in line with the literatures reporting that the circulat-
ing MMP-9 level is higher in patients with dyslipidemia 
[46], hypertension [26, 47], hyperglycemia [48] and cen-
tral obesity [49]. It has also been previously demonstrated 
that MMP-9 level is correlated with blood triglycerides 
level [50] while our data show that the serum MMP-9 
level is higher in people with hypertriglyceridemia.
Plenty of studies have demonstrated the relationship 
between MMP‑9 and diabetes mellitus
It has been demonstrated that the activities of MMP-9 in 
plasma and vascular cells are also higher in rodent mod-
els of diabetes mellitus [48]. Previous studies have dem-
onstrated that MMP-9 level is significantly increased 
in patients under diabetic condition [10, 51]. Patients 
suffering from type 1 diabetes mellitus have been dem-
onstrated to have significantly higher abundance of circu-
lating MMP-9 [10]. MMP-9 activity has also been shown 
to be significantly higher in patients with type 2 diabe-
tes mellitus [48, 52]. Notably, it is observed in the pre-
sent study that subjects with fasting blood glucose equals 
or exceed 5.5  mmol/L have a significant higher level of 
serum MMP-9 level compared to subjects without hyper-
glycemia, suggesting that the upregulation of MMP-9 
occurs before the fasting blood glucose level has reached 
to clinical diabetic level. MMP-9 is associated with sev-
eral pathological changes of diabetes mellitus including 
diabetic retinopathy [52], diabetic nephropathy [10] and 
diabetic microvascular complications due to its contri-
bution in microvascular remodeling [53]. Upregulation 
of MMP-9 has been observed during the development 
of diabetic microvascular complications [53]. The high 
abundance of MMP-9 is also associated with the recruit-
ment of leukocytes to lesions and fibrosis of the micro-
vascular wall [54, 55]. The activation of MMP-9 has been 
demonstrated to contribute to the development of retin-
opathy by increasing vascular permeability and enhanc-
ing apoptosis of retinal capillary cells [52]. Suppression 
of hyperglycemia-induced activation of MMP-9 can ame-
liorate apoptosis of retinal capillary cells [45]. Genetic 
variances on MMP-9 gene are demonstrated to be asso-
ciated with the risk of developing diabetic microvascu-
lar complications. A study of meta-analysis has revealed 
that mutation of the promoter of MMP-9 gene decreases 
the risk of diabetic nephropathy [53]. The involvement of 
MMP-9 in the early hypertensive remodeling has been 
demonstrated [26] while MMP-9 has been suggested as 
a biomarker for acute coronary syndrome [56]. MMP-9 
has also been suggested to be involved in plaque forma-
tion, destabilization and rupture [27, 57]. High abun-
dance of MMP-9 has been observed in an animal model 
of hypertension [58] and clinically in women with ges-
tational hypertension [59]. It has been demonstrated in 
the Framingham Offspring Study that high MMP-9 level 
is related to higher risk of blood pressure progression 
[60]. The incidence of coronary heart disease has been 
reported to be associated with the serum level of MMP-9 
[61]. Interestingly, a study in middle-aged population 
revealed that the circulating level of MMP-9 is associated 
with psychosocial instruments covered depression, hos-
tile affect, cynicism and sense of coherence, suggesting 
that the MMP-9 level might not only associated with the 
traditional risk factors but also with the psychosocial risk 
factors of cardiovascular diseases [62]. In this study, sub-
jects with MetS or subjects with either one of metabolic 
abnormalities are observed to have significantly higher 
abundance of MMP-9 in the blood. These data support 
the speculation that hyperglycemia-induced upregula-
tion of MMP-9 might be one of the reasons for diabetic 
patients having two- to four-fold increase in risk of 
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having cardiovascular diseases when compared to non-
diabetic people [63].
Notably, it has been observed that both ET-1 and 
MMP-9 are positively correlated with age but not gender. 
The age of subjects with central obesity and dyslipidemia 
are significantly higher than those without central obe-
sity and dyslipidemia in this study. It has been previously 
reported that the prevalence of MetS increases with age 
[64, 65]. It has been demonstrated in the present study 
that not only the incidence rates of those cardio-meta-
bolic abnormalities [64, 65], but also these two endothe-
lial biomarkers are associated with age. The increases in 
these endothelial biomarkers with advancing age might 
partly explain the increase in the incidence rates of car-
diovascular diseases [66] and diabetes mellitus [67] in 
elderly.
Elevated circulating levels of ET‑1 and MMP‑9 in people 
with MetS might be related to higher risk of cancer 
development
There are literatures supporting that people with MetS 
have increased risk of developing common cancers due 
to the association between the MetS components and 
etiology or progression of certain cancers [68]. Can-
cer patients with obesity tend to manifest more local-
ized tumors, earlier relapse and lower survival rate [69]. 
Studies have shown that obesity is linked to cancer of 
the gastricardia, cholangiocarcinoma, esophageal adeno-
carcinoma [70], multiple myeloma and large B cell lym-
phoma in men [71] and breast cancer in women [70]. In 
addition, the association of dyslipidemia/hyperglycemia 
and cancers has been reported. The incidences of lung 
cancer [70], non-hodgkin lymphoma [71] and breast can-
cer [72, 73] are associated with low circulating level of 
HDL-C. Type 2 diabetes mellitus is regarded as a predic-
tor of mortality from cancer including colon cancer, pan-
creatic cancer, lung and breast cancer in female, and liver 
and bladder cancer in male [36]. The increase in circulat-
ing levels of MMP-9 and ET-1 could be a possible link-
age between MetS and cancers. It has been demonstrated 
that ET-1 and MMP-9 are both related to cancer develop-
ment, progression and metastasis by suppressing apop-
tosis, and enhancing angiogenesis and mitosis [13, 14]. 
It has been demonstrated that ET-1 protects colon carci-
noma cells from FasL-induced apoptosis [74] and prevent 
rat fibroblasts and human endothelial cells from serum-
deprivation-induced apoptosis [13]. A transgenic animal 
study has demonstrated the involvement of MMP-9 in 
FasL-induced apoptosis by showing a significantly lower 
level of apoptosis in MMP-9 deficient mice [75]. In vitro 
studies revealed that ET-1 also serves as a mitogen in 
cell lines of colorectal cancer, ovarian cancer, prostate 
cancer, epithelial tumors, sarcoma and melanoma [13]. 
It has also been demonstrated in a co-culture in  vitro 
study that ET-1 generated by human ovarian cancer cells 
can stimulate the carcinoma-associated fibroblasts [76]. 
Besides cancer cells, ET-1 also promotes the growth of 
endothelial cells and vascular smooth muscle cells, hence 
may facilitate angiogenesis in tumor [13]. It has been 
demonstrated that ET-1 is able to stimulate angiogen-
esis in a rat corneal model with same efficacy to vascu-
lar endothelial growth factor (VEGF) [77] and stimulate 
angiogenesis in subcutaneously implanted matrigel plugs 
in mice while co-treat with VEGF [78]. A study in 2008 
has demonstrated the involvement of MMP-9 in activat-
ing VEGF and thus promotes angiogenesis [79]. Another 
study using transgenic zebra fish has demonstrated that 
ET-1 overexpression can lead to hepatocarcinagenesis 
[80]. It is reported that ET-1 can stimulate the expression 
of MMP-9, which contributes to the growth and metas-
tasis of cancer [80]. The increase in circulating ET-1 and 
MMP-9 observed in the subjects with MetS and with cer-
tain metabolic abnormalities in the present study could 
be a possible explanation to the increased risk of having 
cancer in people with MetS while cancer patients with 
MetS might have a faster development of cancer due to 
the elevated circulating level of ET-1 and MMP-9.
In conclusion, the increase in circulating levels of ET-1 
and MMP-9 has been observed in subjects with MetS 
and might be associated with the underlying causes of the 
increased risk of cardiovascular diseases, diabetes melli-
tus and cancer in people with MetS. Further research is 
needed to investigate the exact role of ET-1 and MMP-9 
in the development of cancer, diabetes and cardiovascu-
lar disease in relation to metabolic syndrome.
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